Mechanical circulatory support devices (MCSDs) are emerging as a valuable therapeutic option for the management of end-stage heart failure. However, although recipients are routinely administered with anti-thrombotic (AT) drugs, thrombosis persists as a severe post-implant complication. Conventional clinical assays and coagulation markers demonstrate partial ability in preventing the onset of thrombosis. Through years, different laboratory techniques have been proposed as potential tools for the evaluation of platelets' hemostatic response in MCSD recipients. Most rely on platelet aggregation tests; they are performed in static or low shear conditions, neglecting the prominent contribution of MCSD shear-induced mechanical load in enhancing platelet activation (PA). On the other hand, those tests able to account for shear-induced PA have limited possibility of effective clinical translation.
Aims and Methods
Advances on this side have been addressed by microfluidic technology. Microfluidic devices have been developed for AT drug monitoring under flow, able to replicate physiological and/or constant shear flow conditions in vitro. In this paper, we present a newly developed microfluidic platform able to expose platelets to MCSD-specific dynamic shear stress patterns. We performed in vitro tests circulating human platelets in the microfluidic platform and quantifying the dynamics of PA by means of the Platelet Activity State (PAS) assay.
Results
Our results prove the feasibility of using microfluidics for the diagnosis of MCSD-related thrombotic risk. This study paves the way for the development of a miniaturized point-of-care device for monitoring AT drug regimen. Such a system may have significant impact on limiting the incidence of thrombosis in MCSD recipients.
StewartG.C., GivertzM.M.Mechanical circulatory support for advanced heart failure: patients and technology in evolution. Circulation.2012; 125(10): 1304–15. Accessed October 4, 2015.
BonacchiM., HarmelinG., BugettiM., SaniG.Mechanical Ventricular Assistance as Destination Therapy for End-Stage Heart Failure: Has it Become a First Line Therapy?Front Surg.2015; 2: 35.
13.
GarbadeJ., BittnerH.B., BartenM.J., MohrF.W.Current trends in implantable left ventricular assist devices. Cardiol Res Pract.2011; 2011: 290561.
14.
SlaughterM.S., RogersJ.G., MilanoC.A., RussellS.D., ConteJ.V., FeldmanD., SunB.Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med.2009; 361(23): 2241–51.
15.
TorregrossaG., MorshuisM., VargheseR., HosseinianL., VidaV., TarziaV., LoforteA., DuveauD.Results with SynCardia total artificial heart beyond 1 year. ASAIO J.2014; 60(6): 626–34.
16.
BartoliC.R., AilawadiG., KernJ.A.Diagnosis, nonsurgical management, and prevention of LVAD thrombosis. J Card Surg.2014; 29(1): 83–94.
17.
StarlingR.C., MoazamiN., SilvestryS.C.Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med.2014; 370(1): 33–40.
18.
TarziaV., BurattoE., BortolussiG., GalloM., BejkoJ., BiancoR., BottioT., GerosaG.Hemorrhage and thrombosis with different LVAD technologies: a matter of flow?Ann Cardiothorac Surg.2014 Nov; 3(6): 582–4.
19.
ChiuW.C., GirdharG., XenosM., AlemuY., SoaresJ.S., EinavS., SlepianM., BluesteinD.Thromboresistance comparison of the HeartMate II ventricular assist device with the device thrombogenicity emulation- optimized HeartAssist 5 VAD. J Biomech Eng.2014; 136(2): 021014.
20.
ThamsenB., BlümelB., SchallerJ., PaschereitC.O., AffeldK., GoubergritsL., KertzscherU.Numerical Analysis of Blood Damage Potential of the HeartMate II and HeartWare HVAD Rotary Blood Pumps. Artif Organs.2015; 39(8): 651–9.
21.
MichelsonA.D.Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program.2011; 2011: 62–9.
22.
KalantziK.I., TsoumaniM.E., GoudevenosI.A., TselepisA.D.Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives. Expert Rev Clin Pharmacol.2012; 5(3): 319–36.
23.
GladdingP., WebsterM., OrmistonJ., OlsenS., WhiteH.Antiplatelet drug nonresponsiveness. Am Heart J.2008; 155(4): 591–9.
24.
KastratiA.New anti-platelet agents: the end of resistance?Thromb Res.2012; 130(Suppl 1): S53–5.
25.
CattaneoM.Mechanisms of variability in antiplatelet agents response. Thromb Res.2012; 130(Suppl 1): S27–8.
ShahP., MehtaV.M., CowgerJ.A., AaronsonK.D., PaganiF.D.Diagnosis of hemolysis and device thrombosis with lactate dehydrogenase during left ventricular assist device support. J Heart Lung Transplant.2014; 33(1): 102–4.
28.
ThenappanT., AndersonA.S., JeevanadhamV., RichJ.D., ShahA.P.Treatment of left ventricular assist device thrombosis with extended catheter-directed intraventricular thrombolytic therapy. Circ Heart Fail.2013; 6(3): e27–9.
29.
BartoliC.R., GhotraA.S., PachikaA.R., BirksE.J., McCantsK.C.Hematologic markers better predict left ventricular assist device thrombosis than echocardiographic or pump parameters. Thorac Cardiovasc Surg.2014; 62(5): 414–8.
30.
TrivediJ.R., SobieskiM.A., SchwartzS., WilliamsM.L., SlaughterM.S.Novel thrombosis risk index as predictor of left ventricular assist device thrombosis. ASAIO J.2013; 59(4): 380–3.
31.
PollerL.International Normalized Ratios (INR): the first 20 years. J Thromb Haemost.2004; 2(6): 849–60.
32.
ManiH., HerthN., KasperA., WendtT., SchuettfortG., WeilY., PfeilschifterW., LinnemannB., HerrmannE., Lindhoff-LastE.Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit.2014; 36(5): 624–31.
33.
SharmaP., ScotlandG., CruickshankM., TassieE., FraserC., BurtonC., CroalB., RamsayC.R., BrazzelliM.The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice: systematic review and economic evaluation. Health Technol Assess.2015; 19(48): 1–172.
BolligerD., SeebergerM.D., TanakaK.A.Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev.2012 Jan; 26(1): 1–13.
38.
SørensenB., IngerslevJ.Thromboelastography and recombinant factor Vila-hemophilia and beyond. Semin Hematol.2004; 41(1 Suppl 1): 140–4. Review.
39.
FavaloroE.J.Clinical utility of the PFA-100. Semin Thromb Hemost.2008; 34(8): 709–33.
40.
EckmanP.M., JohnR.Bleeding and thrombosis in patients with continuous-flow ventricular assist devices. Circulation.2012; 125(24): 3038–47.
41.
ArdillonL., TernisienC., FouassierM., SigaudM., LefrançoisA., PacaultM., RibeyrolO., FressinaudE., BoisseauP., TrossaërtM.Platelet function analyser (PFA-100) results and von Willebrand factor deficiency: a 16-year ‘real-world’ experience. Haemophilia.2015; 21(5): 646–52.
42.
YangH., LangS., ZhaiZ., LiL., KahrW.H., ChenP., BrkićJ., SpringC.M., FlickM.J., DegenJ.L., FreedmanJ., NiH.Fibrinogen is required for maintenance of platelet intracellular and cell-surface P-selectin expression. Blood.2009; 114(2): 425–36.
43.
LuQ., MalinauskasR.A.Comparison of two platelet activation markers using flow cytometry after in vitro shear stress exposure of whole human blood. Artif Organs.2011; 35(2): 137–44.
44.
LöfflerC., StraubA., BasslerN., PerniceK., BeyersdorfF., BodeC., SiegenthalerM.P., PeterK.Evaluation of platelet activation in patients supported by the Jarvik 2000* high-rotational speed impeller ventricular assist device. J Thorac Cardiovasc Surg.2009; 137(3): 736–41.
45.
NascimbeneA., HernandezR., GeorgeJ.K., ParkerA., BergeronA.L., PradhanS., VijayanK.V., CivitelloA., SimpsonL., NawrotM., LeeV.V., MallidiH.R., DelgadoR.M., DongJ.F., FrazierO.H.Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transplant.2014; 33(5): 470–7.
46.
HuH., DaleskogM., LiN.Influences of fixatives on flow cytometric measurements of platelet P-selectin expression and fibrinogen binding. Thromb Res.2000; 100(3): 161–6.
47.
SchmidtV., HilbergT., FrankeG., GläserD., GabrielH.H.Paraformaldehyde fixation induces a systematic activation of platelets. Platelets.2003; 14(5): 287–94.
48.
AtarO.D., EisertC., PokovI., SerebruanyV.L.Stability validation of paraformaldehyde-fixed samples for the assessment of the platelet PECAM-1, P-selectin, and PAR-1 thrombin receptor by flow cytometry. J Thromb Thrombolysis.2010; 30(1): 79–83.
49.
AshbrookM., WalengaJ.M., SchwartzJ., HerouxA., JeskeW.P., EscalanteV., BakhosM.Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen. Clin Appl Thromb Hemost.2013; 19(3): 249–55.
50.
BluesteinD., GirdharG., EinavS., SlepianM.J.Device thrombogenicity emulation: a novel methodology for optimizing the thromboresistance of cardiovascular devices. J Biomech.2013; 46(2): 338–44.
51.
JestyJ., BluesteinD.Acetylated prothrombin as a substrate in the measurement of the procoagulant activity of platelets: elimination of the feedback activation of platelets by thrombin. Anal Biochem.1999; 272(1): 64–70.
52.
ChiuW.C., SlepianM.J., BluesteinD.Thrombus formation patterns in the HeartMate II ventricular assist device: clinical observations can be predicted by numerical simulations. ASAIO J.2014; 60(2): 237–40.
53.
MaromG., ChiuW.C., CrosbyJ.R., DeCookK.J., PrabhakarS., HornerM., SlepianM.J., BluesteinD.Numerical model of full-cardiac cycle hemodynamics in a total artificial heart and the effect of its size on platelet activation. J Cardiovasc Transl Res.2014; 7(9): 788–96.
54.
SlepianM.J., AlemuY., GirdharG., SoaresJ.S., SmithR.G., EinavS., BluesteinD.The Syncardia(™) total artificial heart: in vivo, in vitro, and computational modeling studies. J Biomech.2013; 46(2): 266–75.
55.
AlemuY., GirdharG., XenosM., SheriffJ., JestyJ., EinavS., BluesteinD.Design optimization of a mechanical heart valve for reducing valve thrombogenicity-A case study with ATS valve. ASAIO J.2010; 56(5): 389–96.
56.
XenosM., GirdharG., AlemuY., JestyJ., SlepianM., EinavS., BluesteinD.Device Thrombogenicity Emulator (DTE)–design optimization methodology for cardiovascular devices: a study in two bileaflet MHV designs. J Biomech.2010; 43(12): 2400–9.
57.
ClaiborneT.E., XenosM., SheriffJ., ChiuW.C., SoaresJ., AlemuY., GuptaS., JudexS., SlepianM.J., BluesteinD.Toward optimization of a novel trileaflet polymeric prosthetic heart valve via device thrombogenicity emulation. ASAIO J.2013; 59(3): 275–83.
58.
PiattiF., SturlaF., MaromG., SheriffJ., ClaiborneT.E., SlepianM.J., RedaelliA., BluesteinD.Hemodynamic and thrombogenic analysis of a trileaflet polymeric valve using a fluid-structure interaction approach. J Biomech.2015; 48(13) 3641–3649.
59.
ConsoloF., ValerioL., BrizzolaS., RotaP., MarazzatoG., VincoliV.T., ReggianiS., RedaelliA., FioreG.B.On the use of the Platelet Activity State assay for the in vitro quantification of platelet activation in blood. recirculating devices for extracorporeal circulation. Artif Organs.2016.
60.
GirdharG., BluesteinD.Biological effects of dynamic shear stress in cardiovascular pathologies and devices. Expert Rev Med Devices.2008; 5(2): 167–81.
61.
SheriffJ., GirdharG., ChiuW.C., JestyJ., SlepianM.J., BluesteinD.Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device. J Thromb Thrombolysis.2014; 37(4): 499–506.
62.
ValerioL., ConsoloF., BluesteinD., TranP., SlepianM., RedaelliA., PappalardoF.Shear-mediated platelet activation in patients implanted with continuous flow LVADs: A preliminary study utilizing the platelet activity state (PAS) assay. Conf Proc IEEE Eng Med Biol Soc.2015: 1255–8.
63.
BastidaE., EscolarG., OrdinasA., SixmaJ.J.Fibronectin is required for platelet adhesion and for thrombus formation on subendothelium and collagen surfaces. Blood.1987 Nov; 70(5): 1437–42.
64.
GiorgioT.D., HellumsJ.D.A cone and plate viscometer for the continuous measurement of blood platelet activation. Biorheology.1988; 25(4): 605–24.
65.
WhitesidesG.M.The origins and the future of microfluidics. Nature.2006; 442(7101): 368–373. Review.
66.
FriendJ., YeoL.Fabrication of microfluidic devices using polydimethylsiloxane. Biomicrofluidics.2010; 4(2). pii: 026502.
67.
GutierrezE., PetrichB.G., ShattilS.J., GinsbergM.H., GroismanA., Kasirer-FriedeA.Microfluidic devices for studies of shear-dependent platelet adhesion. Lab Chip.2008; 8(9): 1486–1495.
68.
HansenR.R., WufsusA.R., BartonS.T., OnasogaA.A., Johnson-PabenR.M., NeevesK.B.High content evaluation of shear dependent platelet function in a microfluidic flow assay. Ann Biomed Eng.2013; 41(2): 250–262.
69.
LiM., KuD.N., ForestC.R.Microfluidic system for simultaneous optical measurement of platelet aggregation at multiple shear rates in whole blood. Lab Chip.2012; 12(7): 1355–62.
70.
NeevesK.B., OnasogaA.A., HansenR.R., LillyJ.J., VenckunaiteD.Sources of variability in platelet accumulation on type 1 fibrillar collagen in microfluidic flow assays. PLoS ONE.2013; 8(1): e54680.
71.
HarrisL.F., RaineyP., Castro-LópezV., O'DonnellJ.S., KillardA.J.A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy. Analyst.2013; 138(17): 4769–76.
72.
LiR., DiamondS.L.Detection of platelet sensitivity to inhibitors of COX-1, P2Y1, and P2Y12 using a whole blood microfluidic flow assay. Thromb Res.2014; 133(2): 203–10.
73.
MaloneyS.F., BrassL.F., DiamondS.L.P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. Integr Biol (Camb).2010; 2(4): 183–92.
74.
LiM., HotalingN.A., KuD.N., ForestC.R.Microfluidic Thrombosis under Multiple Shear Rates and Antiplatelet Therapy Doses. PLoS ONE2014; 9(1): e82493.
75.
HosokawaK., OhnishiT., SameshimaH., MiuraN., ItoT., KoideT., MaruyamaI.Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost.2013; 109(1): 102–11.
